# Hidden risks associated with occupational pesticide exposure in women with breast cancer: High frequency of the Luminal B molecular subtype and occurrence of poor prognostic features

**Authors:** Isabella C. Cazagranda, Rafaela Frederico de Almeida, Lucca L. Smaniotto, Maria Paula de Andrade Berny, Carolina Coradi, Daniel Rech, Carolina Panis, Guilherme F. Silveira, Elingarami Sauli, Elingarami Sauli, Elingarami Sauli, Elingarami Sauli, Elingarami Sauli, Elingarami Sauli, Elingarami Sauli, Elingarami Sauli

PMC · DOI: 10.1371/journal.pone.0339471 · PLOS One · 2026-02-05

## TL;DR

This study finds that rural women exposed to pesticides are more likely to develop aggressive breast cancer subtypes and face worse outcomes.

## Contribution

The study links occupational/household pesticide exposure to increased prevalence of aggressive breast cancer subtypes and poor prognostic features in rural women.

## Key findings

- Exposed women had higher prevalence of Luminal B subtype (32.83%) compared to unexposed (37.78% Luminal A).
- Exposed patients showed higher recurrence (10.19%) and chemoresistance (21.26%) compared to unexposed patients.
- Pesticide-exposed patients were more likely to have distant metastases (1.4x) and lymph node invasion (1.3x).

## Abstract

Human pesticide exposure is a common event in countries with strength conventional agriculture, such as Brazil. Despite evidence on the negative impact of pesticides on human health, the country stands out among the top three pesticide consumers globally. The implications of this scenario on rural workers health, particularly women, is completely neglected, resulting in chronic illness such as breast cancer. Objective: In this study, we analyzed the impact of occupational/household chronic exposure to pesticides on the clinicopathological profile of breast cancer in rural women from Paraná southwest, a predominantly rural landscape with large pesticide uses. Methods: A total of 349 women were included in the study. After a structured interview, women were categorized as exposed (n = 208) or unexposed (n = 141) to pesticides. Clinicopathological data were collected from medical records. Descriptive and inferential statistical methods were used to characterize and compare the sample. The Chi-square test and Fisher’s exact test were used to evaluate differences between the molecular subtypes and clinicopathological variables of patients. Results: Exposed patients had a prevalence of the Luminal B subtype (32.83%), while unexposed patients had a prevalence of the Luminal A molecular subtype (37.78%, p <= 0.05). Exposed patients also had higher disease recurrence (10.19%), chemoresistance (21.26%), than unexposed patients (p <= 0.05). Breast cancer patients exposed to pesticides were also more likely to have distant metastases (1.4 times) and lymph node invasion (1.3 times) compared to patients not exposed. Conclusions: These findings indicate that pesticide exposure favors the occurrence of more aggressive breast cancer.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, PALB2 (partner and localizer of BRCA2) [NCBI Gene 79728] {aka BROVCA5, FANCN, PNCA3}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}
- **Diseases:** ACADEMIC EDITOR (MESH:D007859), breast (MESH:D061325), Breast cancer (MESH:D001943), oncogenesis (MESH:D063646), mesothelioma (MESH:D008654), inflammatory (MESH:D007249), angiolymphatic emboli (MESH:D020766), chronic illness (MESH:D002908), non-Hodgkin lymphoma (MESH:D008228), distant metastasis (MESH:D009362), death (MESH:D003643), lymph node (MESH:D000072717), hypoxic (MESH:D002534), B (MESH:D006509), Stage II cancer (MESH:D009369), immunotoxicity,9 (MESH:C557826), lymph nodal metastases (MESH:D008207), carcinogenic (MESH:D011230), immune dysregulation (OMIM:614878), endocrine disrupting (MESH:D004700)
- **Chemicals:** methotrexate (MESH:D008727), carboplatin (MESH:D016190), 5-fluorouracil (MESH:D005472), water (MESH:D014867), docetaxel (MESH:D000077143), corticosterone (MESH:D003345), 2,4-D (MESH:D015084), 17beta-estradiol (MESH:D004958), Glyphosate (MESH:C010974), 2,4-dichlorophenoxyacetic (-), paclitaxel (MESH:D017239), doxorubicin (MESH:D004317), Atrazine (MESH:D001280), trastuzumab (MESH:D000068878), cyclophosphamide (MESH:D003520)
- **Species:** Homo sapiens (human, species) [taxon 9606], Glycine max (soybean, species) [taxon 3847]
- **Mutations:** rs7438135

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12875504/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12875504/full.md

## References

81 references — full list in the complete paper: https://tomesphere.com/paper/PMC12875504/full.md

---
Source: https://tomesphere.com/paper/PMC12875504